Francesco De Rose1, Miriam Braeuer1, Sten Braesch-Andersen2, Angela M Otto3, Katja Steiger4,5, Sybille Reder1, Sabine Mall6, Stephan Nekolla1, Markus Schwaiger1, Wolfgang A Weber1, Armando Bartolazzi7,8, Calogero D'Alessandria9. 1. Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, München, Germany. 2. Mabtech AB Research Laboratory, Stockholm, Sweden. 3. Munich School of Biomedical Engineering, Technische Universität München, Garching, Germany. 4. Institute of Pathology, Klinikum rechts der Isar, Technische Universität München, München, Germany. 5. Comparative Experimental Pathology, Klinikum rechts der Isar, Technische Universität München, München, Germany. 6. III, Medical Department, Klinikum rechts der Isar, Technische Universität München, München, Germany. 7. Pathology Research Laboratory, Cancer Center Karolinska, Karolinska Hospital, Stockholm, Sweden; and. 8. Pathology Research Laboratory, Sant'Andrea University Hospital, Rome, Italy. 9. Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, München, Germany calogero.dalessandria@tum.de.
Abstract
Preoperative characterization of thyroid nodules is challenging since thyroid scintigraphy fails to distinguish between benign and malignant lesions. Galectin-3 (gal-3) is expressed in well-differentiated and in undifferentiated thyroid cancer types but not in normal thyrocytes and benign thyroid lesions. Herein, we aimed to validate gal-3 targeting as a specific method to detect non-radioiodine-avid thyroid cancer in thyroid orthotopic tumor models. Methods: Papillary (BcPAP) and anaplastic (CAL62 and FRO82-1) thyroid carcinoma cell lines were characterized via Western blot and polymerase chain reaction for gal-3 and sodium-iodide symporter (NIS) expression. An 89Zr-labeled F(ab')2 antigal-3 was generated and characterized for binding versus 125I on 2- and 3-dimensional cell cultures. The thyroid carcinoma cells were inoculated into the left thyroid lobe of athymic nude mice, and the orthotopic tumor growth was monitored via ultrasound and fluorescence molecular tomography. Head-to-head PET/CT comparison of 124I versus 89Zr-deferoxamine (DFO)-F(ab')2 antigal-3 was performed, followed by biodistribution studies and immunohistochemical analysis for gal-3 and NIS expression. Results: The thyroid carcinoma cells investigated were invariably gal-3-positive while presenting low or lost NIS expression. 89Zr-DFO-F(ab')2 antigal-3 tracer showed high affinity to gal-3 (dissociation constant, ∼3.9 nM) and retained immunoreactivity (>75%) on 2-dimensional cell cultures and on tumor spheroids. 125I internalization in FRO82-1, BcPAP, and CAL62 was directly dependent on NIS expression, both in 2-dimensional and tumor spheroids. PET/CT imaging showed 89Zr-DFO-F(ab')2 antigal-3 signal associated with the orthotopically implanted tumors only; no signal was detected in the tumor-free thyroid lobe. Conversely, PET imaging using 124I showed background accumulation in tumor-infiltrated lobe, a condition simulating the presence of non-radioiodine-avid thyroid cancer nodules, and high accumulation in normal thyroid lobe. Imaging data were confirmed by tracer biodistribution studies and immunohistochemistry. Conclusion: A specific and selective visualization of thyroid tumor by targeting gal-3 was demonstrated in the absence of radioiodine uptake. Translation of this method into the clinical setting promises to improve the management of patients by avoiding the use of unspecific imaging methodologies and reducing unnecessary thyroid surgery.
Preoperative characterization of thyroid nodules is challenging since thyroid scintigraphy fails to distinguish between benign and malignant lesions. Galectin-3 (gal-3) is expressed in well-differentiated and in undifferentiated thyroid cancer types but not in normal thyrocytes and benign thyroid lesions. Herein, we aimed to validate gal-3 targeting as a specific method to detect non-radioiodine-avid thyroid cancer in thyroid orthotopic tumor models. Methods: Papillary (BcPAP) and anaplastic (CAL62 and FRO82-1) thyroid carcinoma cell lines were characterized via Western blot and polymerase chain reaction for gal-3 and sodium-iodide symporter (NIS) expression. An 89Zr-labeled F(ab')2 antigal-3 was generated and characterized for binding versus 125I on 2- and 3-dimensional cell cultures. The thyroid carcinoma cells were inoculated into the left thyroid lobe of athymic nude mice, and the orthotopic tumor growth was monitored via ultrasound and fluorescence molecular tomography. Head-to-head PET/CT comparison of 124I versus 89Zr-deferoxamine (DFO)-F(ab')2 antigal-3 was performed, followed by biodistribution studies and immunohistochemical analysis for gal-3 and NIS expression. Results: The thyroid carcinoma cells investigated were invariably gal-3-positive while presenting low or lost NIS expression. 89Zr-DFO-F(ab')2 antigal-3 tracer showed high affinity to gal-3 (dissociation constant, ∼3.9 nM) and retained immunoreactivity (>75%) on 2-dimensional cell cultures and on tumor spheroids. 125I internalization in FRO82-1, BcPAP, and CAL62 was directly dependent on NIS expression, both in 2-dimensional and tumor spheroids. PET/CT imaging showed 89Zr-DFO-F(ab')2 antigal-3 signal associated with the orthotopically implanted tumors only; no signal was detected in the tumor-free thyroid lobe. Conversely, PET imaging using 124I showed background accumulation in tumor-infiltrated lobe, a condition simulating the presence of non-radioiodine-avid thyroid cancer nodules, and high accumulation in normal thyroid lobe. Imaging data were confirmed by tracer biodistribution studies and immunohistochemistry. Conclusion: A specific and selective visualization of thyroid tumor by targeting gal-3 was demonstrated in the absence of radioiodine uptake. Translation of this method into the clinical setting promises to improve the management of patients by avoiding the use of unspecific imaging methodologies and reducing unnecessary thyroid surgery.
Authors: A Bartolazzi; A Gasbarri; M Papotti; G Bussolati; T Lucante; A Khan; H Inohara; F Marandino; F Orlandi; F Nardi; A Vecchione; R Tecce; O Larsson Journal: Lancet Date: 2001-05-26 Impact factor: 79.321
Authors: Lodovico Rosato; Nicola Avenia; Paolo Bernante; Maurizio De Palma; Giuseppe Gulino; Pier Giorgio Nasi; Maria Rosa Pelizzo; Luciano Pezzullo Journal: World J Surg Date: 2004-02-17 Impact factor: 3.352
Authors: C J Anderson; J M Connett; S W Schwarz; P A Rocque; L W Guo; G W Philpott; K R Zinn; C F Meares; M J Welch Journal: J Nucl Med Date: 1992-09 Impact factor: 10.057
Authors: Emanuel Peplau; Francesco De Rose; Andreas Eichinger; Sybille Reder; Markus Mittelhäuser; Giorgia Scafetta; Markus Schwaiger; Wolfgang A Weber; Armando Bartolazzi; Calogero D'Alessandria; Arne Skerra Journal: Sci Rep Date: 2021-04-01 Impact factor: 4.379